Magnani M, Rossi L, Fraternale A, Silvotti L, Quintavalla F, Piedimonte G, Matteucci D, Baldinotti F, Bendinelli M
Institute of Biochemistry, University of Urbino, Italy.
Vet Immunol Immunopathol. 1995 May;46(1-2):151-8. doi: 10.1016/0165-2427(94)07014-x.
We have evaluated in vitro and in vivo whether it is possible to protect cat macrophages from feline immunodeficiency virus (FIV) infection by the administration of dideoxycytidine 5'-triphosphate (DDCTP). Since cell membranes are impermeable to phosphorylated drugs we have encapsulated DDCTP into autologous erythrocytes and modified erythrocyte membranes to target these drug-loaded cells to macrophages. DDCTP-loaded erythrocytes reduced FIV production by macrophages infected in vitro or obtained from naturally or experimentally infected cats. The same treatment protected the majority of peritoneal macrophages during a 7 month experimental FIV infection and reduced the percentage of circulating lymphocytes stained with an anti-p24 antibody. These results suggest that the administration of nucleoside analogues in phosphorylated form is feasible and their targeting to macrophages reduces FIV infection in vitro and in vivo.
我们已经在体外和体内评估了通过给予双脱氧胞苷5'-三磷酸（DDCTP）来保护猫巨噬细胞免受猫免疫缺陷病毒（FIV）感染的可能性。由于细胞膜对磷酸化药物不可渗透，我们已将DDCTP封装到自体红细胞中，并对红细胞膜进行修饰，以使这些载药细胞靶向巨噬细胞。负载DDCTP的红细胞减少了体外感染或从自然感染或实验感染的猫获得的巨噬细胞产生的FIV。在为期7个月的实验性FIV感染期间，相同的处理保护了大多数腹膜巨噬细胞，并降低了用抗p24抗体染色的循环淋巴细胞的百分比。这些结果表明，以磷酸化形式给予核苷类似物是可行的，并且它们靶向巨噬细胞可在体外和体内减少FIV感染。
